We know a lot of our patients and families have been impacted by the recall of NatPara in 2019 with many of you on the compassionate use program that is slated to close at the end of 2024. Todd Talarico recently had the opportunity to speak to the Head of Patient Advocacy for Ascendis Pharma, and they may have good news on the horizon.
Ascendis Pharma has submitted their parathyroid hormone drug, called TransCon PTH, to the FDA for approval. A big thank you to the APS Type 1 patients who participated in their clinical trial. This product is also pretty exciting because once serum levels regulated, this product is a WEEKLY versus a DAILY injection treatment, which we’re sure would be very welcoming for our community.
We understand that Ascendis Pharma is optimistic that FDA approval could come as soon as April 2023. Ascendia has committed to keeping us informed and working with our community to transition to TransCon PTH whenever possible. More to come, but this is another exciting advance in treatment for our community. As we get more information, we will make sure to post updates on the website.